Clinical Trials Browser

Phase 1 × Has results × Other solid neoplasm × Clear all

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

MESO-PRIME

POLAR

KZR-261 in Subjects With Advanced Solid Malignancies

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

MINOTAUR

LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

HCW9218 in Select Advanced Solid Tumors

A Study of LY3405105 in Participants With Advanced Cancer

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

AMG 404 in Patients With Advanced Solid Tumors

MK-3475-A17

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

CAR T Cells in Mesothelin Expressing Cancers

First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

8479217

FPT155-001

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors

A Phase I Study of TAS-102 in Solid Tumors

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

COMBO

A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

ONO-4538 Phase I Study in Patients With Solid Tumor

PTX-35 in Patients With Advanced Solid Tumors

A Study Of PF-04449913 Administered Alone In Select Solid Tumors

A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors

A Study of GFH018 in Patients With Advanced Solid Tumors

Phase I/Ib Multiple Ascending Dose Study in China